2-cyclopentyl-5-(prop-2-enylamino)-4-oxazolecarbonitrile : no description available [CHeBI]
| ID Source | ID |
|---|---|
| PubMed CID | 44142074 |
| CHEMBL ID | 1867190 |
| CHEBI ID | 93508 |
| Synonym |
|---|
| NCGC00183417-01 |
| MLS002276534 |
| smr001318072 |
| HMS2215K10 |
| HMS3329L07 |
| CHEMBL1867190 |
| CHEBI:93508 |
| 2-cyclopentyl-5-(prop-2-enylamino)-4-oxazolecarbonitrile |
| Q27165203 |
| Class | Description |
|---|---|
| oxazole | An azole based on a five-membered heterocyclic aromatic skeleton containing one N and one O atom. |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) |
|---|---|---|---|---|
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 100.0000 | AID540317 |
| parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 79.4328 | AID743266 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 89.1251 | AID588590 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13ISSN: 1934-9300 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 ISSN: 1552-4922 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 ISSN: 1557-8127 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | 2022 | The Journal of biological chemistry, 08, Volume: 298, Issue:8 ISSN: 1083-351X | |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | 2022 | The Journal of biological chemistry, 08, Volume: 298, Issue:8 ISSN: 1083-351X | |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13ISSN: 1934-9300 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 ISSN: 1552-4922 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 ISSN: 1557-8127 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13ISSN: 1934-9300 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 ISSN: 1552-4922 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 ISSN: 1557-8127 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 ISSN: 1945-7170 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 ISSN: 1945-7170 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| gaboxadol | oxazole | 0 | 0 | low | 0 | 0 | 0 | 0 | 0 | 0 | |||
| sulfamoxole | oxazole; sulfonamide antibiotic; sulfonamide | antimicrobial agent; drug allergen | 0 | 0 | low | 0 | 0 | 0 | 0 | 0 | 0 | ||
| 2-[(4-fluorophenoxy)methyl]-5-[3-(1-imidazolyl)propylamino]-4-oxazolecarbonitrile | oxazole | 0 | 0 | low | 0 | 0 | 0 | 0 | 0 | 0 | |||
| 2-[(2-fluorophenoxy)methyl]-5-[3-(1-imidazolyl)propylamino]-4-oxazolecarbonitrile | oxazole | 0 | 0 | low | 0 | 0 | 0 | 0 | 0 | 0 | |||
| 2-(2-furanyl)-5-(2-furanylmethylamino)-4-oxazolecarbonitrile | oxazole | 0 | 0 | low | 0 | 0 | 0 | 0 | 0 | 0 | |||
| 5-(4-morpholinyl)-2-thiophen-2-yl-4-oxazolecarbonitrile | oxazole | 0 | 0 | low | 0 | 0 | 0 | 0 | 0 | 0 | |||
| 2-[(4-fluorophenoxy)methyl]-5-(1-piperidinyl)-4-oxazolecarbonitrile | oxazole | 0 | 0 | low | 0 | 0 | 0 | 0 | 0 | 0 | |||
| 5-(2-oxolanylmethylamino)-2-thiophen-2-yl-4-oxazolecarbonitrile | oxazole | 0 | 0 | low | 0 | 0 | 0 | 0 | 0 | 0 | |||
| 5-(3,5-dimethyl-1-piperidinyl)-2-(2-furanyl)-4-oxazolecarbonitrile | oxazole | 0 | 0 | low | 0 | 0 | 0 | 0 | 0 | 0 | |||
| chivosazole f | oxazole | 0 | 0 | low | 0 | 0 | 0 | 0 | 0 | 0 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inflammation | 0 | 2010 | 2010 | 14.0 | high | 0 | 0 | 0 | 1 | 0 | 0 | |
| Innate Inflammatory Response | 0 | 2010 | 2010 | 14.0 | high | 0 | 0 | 0 | 1 | 0 | 0 |